Hormonal
Elevated circulating branched-chain amino acid (BCAA) levels are strongly associated with insulin resistance and type 2 diabetes, potentially acting as mediators through mTORC1 activation and accumulation of toxic metabolites like acylcarnitines and ceramides.
If you have insulin resistance or type 2 diabetes, high levels of branched-chain amino acids (found in protein) in your blood are linked to worse metabolic health. While protein is essential, simply consuming more BCAAs may not help and could potentially worsen insulin resistance in susceptible individuals. Focus on overall metabolic health and consult a provider before high-dose BCAA supplementation.
higher levels of BCAA tracked with older age, male sex, and metabolic syndrome, as well as with obesity, cardiovascular risk, dyslipidemia, hypertension, and uric acid... Impaired function of BCAT and BCKDH has been posited... with consequent accumulation of branched chain ketoacids and metabolites such as diacylglycerol and ceramide... potentially contributing to the development of further insulin resistance
Why this rating
The paper is a review of observational and mechanistic studies; while associations are strong, causal directionality is debated (Mendelian randomization results are mixed).
Source
Diabetes and branched‐chain amino acids: <scp>W</scp>hat is the link?
Zachary T. Bloomgarden · Journal of Diabetes · 2018
DOI 10.1111/1753-0407.12645
More from this paper
- Bariatric surgery, specifically Roux-en-Y gastric bypass, reduces BCAA levels and improves insulin sensitivity, an effect not seen with weight loss alone via gastric banding.Moderate
- Dietary restriction of branched-chain amino acids can improve insulin sensitivity and increase energy expenditure in animal models, suggesting a potential therapeutic avenue for metabolic disease.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →